Answers are grounded in this paper and cite their sources.
Even at the era of T-cell redirecting therapies, patients with relapsed or refractory multiple myeloma (RRMM) presenting extramedullary disease (EMD) and/or high risk cytogenetic abnormalities (HRCA) constitute a particularly challenging subgroup with lower overall response rate (ORR) and poorer survival outcomes [ 1 , 2 ]. A sub-analysis of the MagnetisMM-3 trial reported an ORR of 0% in patients with ISS stage III disease and HRCA or EMD, compared to ORRs of 47.4% and 71.4% in patients with ISS stages I and II with EMD or HRCA, respectively [ 3 , 4 ]. Teclistamab achieved an ORR of 63% and a median progression-free survival (PFS) of 11.3 months in MajesTec-1 trial [ 5 , 6 ]. In real-life setting, PFS for patients with EMD was 3.7 months vs 11.3 months for patients without EMD and ORR decreased at 37.2% [ 7 ].
No takes yet. Share an insight, caveat, or question.
Chalopin et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: